Actelion Pharmaceuticals Ltd

Hoffmann-la Roche Inc.

Idorsia Pharmaceuticals Ltd

Olivier Houille

Emmanuel Meyer

Francis Hubler

Heinz Fretz

Eva Caroff

Kurt Hilpert

Jean Ackermann

Dorte Renneberg

David Banner

Hans Peter Wessel

Klaus Gubernator

Leo Alig

Gerard Schmid

Paul Hadvary

Beat Wirz

Thomas B Tschopp

Simon Stamm

Ludvik Labler

Thomas Weller

Holger Kuehne

Ulrike Obst

Alexander Chucholowski

Albrecht Edenhofer

Klaus Muller

Lutz Weber

Anja Fecher

G Erard Schmid

Katrin Groebke

Volker Breu

Thierry Kimmerlin

Markus Riederer

Matthias Steger

Thomas Giller

Oliver Valdenaire

Klaus M Uller

Katrin Groebke Zbinden

Markus Gude

David Lehmann

Markus Von Raumer

Stefan Abele

Julien Pothier

Jacques-Alexis Funel

Mark Murphy

Emmanuel Meyers

Günter Schwalm

Markus Isler

Olivier Valdenaire

Katharina Reichenbaecher

Stéphanie Combes

Stephanie Combes

The invention relates to indole carboxamide derivatives of formula (I), wherein R, R, R, R, Rand Rare as defined in the description, their preparation and their use as pharmaceutically active compounds.

Indole carboxamide derivatives as P2X7 receptor antagonist

The invention relates to indole carboxamide derivatives of formula (I), wherein R, R, R, R, R, R, R, R, R, Rand n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

[object Object]

The invention relates to heterocyclic amide derivatives of formula (I), 

Heterocyclic amide derivatives as P2X7 receptor antagonists

The invention relates to heterocyclic amide derivatives of formula (I), wherein R, R, R, R, R, n, m, p and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.

The invention relates to heterocyclic amide derivatives of formula (I), wherein R, R, R, R, n and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.

The invention relates to heterocyclic amide derivatives of formula (I), wherein R, R, R, R, R, X, Y and n are as defined in the description, their preparation and their use as pharmaceutically active compounds. 

The present invention relates to thiazole derivatives of formula I and their use as P2Yreceptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. 

Thiazole derivatives and their use as P2Y12 receptor antagonists

The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Yreceptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I). 

The invention relates to crystalline salts of isobutyric acid (1R*,2R*,4R*)-2-(2-{[3-(4,7 -dimethoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester, processes for the preparation thereof, pharmaceutical compositions containing said crystalline salts, and their use as medicaments, especially as calcium channel blockers.

Salts of isobutyric acid (1 R*, 2R*, 4R*)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester

The invention relates to compounds of Formula (I) wherein R, R, R, R, R, m and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers. 

Tetrahydronaphthalene compounds

The invention relates to compounds of formula (I) wherein R, R, R, R, A, B, W and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers. 

Bridged tetrahydronaphthalene derivatives

The present invention relates to 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine derivatives and their use as P2Yreceptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines

The invention relates to 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives and their use as potent 'chemoattractant receptor-homologous molecule expressed on Th2 cells' antagonists in the treatment of prostaglandin mediated diseases, to pharmaceutical compositions containing these derivatives and to processes for their preparation.

2-sulfanyl-benzoimidazol-1-yi-acetic acid derivatives as CRTH2 antagonists

The invention relates to compounds of formula (I), wherein R, R, R, R, R, R, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers. 

Bridged six-membered ring compounds

The present invention relates to 2-aminocarbonyl-pyridine derivatives of Formula (I) and their use as P2Yreceptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis. 

2-aminocarbonyl-pyridine derivatives

Growing community of inventors

Hofstetten, Switzerland

Kurt Hilpert